Stocktoria
ImmunityBio, Inc. IBRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-07-28
ImmunityBio, Inc. statistics & valuation
Market cap$9.1B
P / S80.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% |
| Net margin | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% |
| FCF margin | -272.6% | -2700.1% | -63881.2% | -173196.2% | -32974.5% |
| Return on assets | -70.0% | -108.0% | -115.6% | -115.0% | -74.0% |
| Return on equity | 70.2% | 84.6% | 99.4% | 92.6% | 142.2% |
| Current ratio | 5.10 | 3.36 | 5.05 | 0.28 | 0.91 |
| Revenue growth | 668.3% | 2270.6% | 159.2% | -74.3% | 54.4% |
Source: SEC EDGAR filings · CIK 0001326110 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.